Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | ||
Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | N/A | Complete | ||
Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
Ravicti | glycerol phenylbutyrate | Urea cycle disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
Rebif | Interferon beta-1a | Clinically isolated syndrome | Do not list | Complete | ||
Reblozyl | luspatercept | beta-thalassemia associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Reblozyl | luspatercept | Myelodysplastic syndromes-associated anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete |